Testing the Combination of Standard Induction Therapy With Gemtuzumab Ozogamicin and Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia

• Status: Suspended
• Trial end date: 2025-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This phase I study hopes to explore how safe and tolerable is the combination of gemtuzumab ozogamicin (GO) and midostaurin, with the standard induction therapy (cytarabine and daunorubicin) in patients with newly diagnosed FLT-3 mutated Acute Myeloid Leukemia (AML). GO is FDA approved for the treatment of adults with newly diagnosed CD33 positive AML and used in combination with chemotherapy, cytarabine and daunorubicin. Midostaurin is FDA approved for use with cytarabine and daunorubicin in patients with FLT3-mutated AML. By combining standard induction therapy with GO and midostaurin, our aim is to investigate a novel approach to treating patients with newly diagnosed FLT3-mutated AML.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: OHSU Knight Cancer Institute
• Collaborators: Fred Hutchinson Cancer Research Center; Oregon Health and Science University; Pfizer
• Treatments: Calicheamicins; Cytarabine; Daunorubicin; Gemtuzumab; Midostaurin; Staurosporine

Criteria

Inclusion Criteria:

• Ability to understand and the willingness to sign a written informed consent document

• Eastern Cooperative Oncology Group (ECOG) performance status =< 2

• Newly diagnosed AML as confirmed by bone marrow and/or peripheral blood examination as indicated, with:

• Confirmed CD33 positivity, per institutional standards

• Presence of FLT3 internal tandem duplication (ITD) or tyrosine kinase domain (TKD) mutation as confirmed by next-generation sequencing (NGS) or other molecular method

• Aspartate aminotransferase (AST) < 2.5 x upper limit of normal (ULN; local laboratory)

• Alanine aminotransferase (ALT) < 2.5 x ULN

• Total bilirubin < 2 x ULN (except for patients with known Gilbert's syndrome)

• Calculated creatinine clearance (according to the Cockcroft-Gault equation) > 40 mL/min OR serum creatinine < 1.5 x the ULN

• Female patients of childbearing potential must agree to use adequate contraception (2 forms of contraception or abstinence) from the screening visit until 6 months following the last dose of study treatment. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately

• Male patients of childbearing potential having intercourse with females of childbearing potential must agree to abstain from heterosexual intercourse or have their partner use 2 forms of contraception from the screening visit until 3 months following the last dose of study treatment. They must also refrain from sperm donation from the screening visit until 90 days following the last dose of study treatment

Exclusion Criteria:

• Isolated myeloid sarcoma (meaning, patients must have blood or marrow involvement to enter study)

• Acute promyelocytic leukemia (per World Health Organization classification)

• Active central nervous system (CNS) involvement by AML, as assessed at discretion of principal investigator (PI) or treating physician and confirmed by lumbar puncture

• Except for hydroxyurea, no other prior systemic anti-AML therapies may have been received prior to starting study therapy

• Known history of veno-occlusive disease

• Known active human immunodeficiency virus (HIV), active hepatitis B or active hepatitis C infection

• Patients with the following will be excluded: uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, serious cardiac arrhythmia, myocardial infarction within 6 months prior to enrollment, New York Heart Association (NYHA) class III or IV heart failure, severe uncontrolled ventricular arrhythmias

• Patients with uncontrolled infection will not be enrolled until infection is treated

• Any concurrent condition that, in the investigator's opinion, would jeopardize the safety of the patient or compliance with the protocol

• Inability to take oral medication

• Hypersensitivity to any study agent, or its excipients, when administered alone

• Pregnancy or breastfeeding at the time of enrollment